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The goal of this study was to provide a feasibility assessment for PET imaging of multiple sclerosis (MS) lesions based on their
decreased myelin content relative to the surrounding normal-appearing brain tissue. The imaging agent evaluated for this purpose
is a molecule that binds strongly and speciﬁcally to myelin basic protein. Physiology-based pharmacokinetic modeling combined
with PET image simulation applied to a brain model was used to examine whether such an agent would allow the diﬀerentiation
of artiﬁcial lesions 4–10mm in diameter from the surrounding normal-looking white and gray matter. Furthermore, we examined
how changes in agent properties, model parameters, and experimental conditions can inﬂuence imageability, identifying a set of
conditions under which imaging of MS lesions might be feasible. Based on our results, we concluded that PET imaging has the
potential to become a useful complementary method to MRI for MS diagnosis and therapy monitoring.
1.Introduction
Multiple sclerosis (MS) is a progressively debilitating neuro-
logical disease ﬁrst described in the mid-19th century [1].
It is named after the multiple lesions of demyelinated white
matter in the central nervous system (CNS) of MS patients.
Between 1980 and 2000, MS was diagnosed based on clinical
symptoms, paraclinical evidence (MRI, urodynamics, elec-
troencephalography potentials measured after visual stimuli,
also called visual evoked potentials), and immunoglobulin
abnormalities of the cerebrospinal ﬂuid (CSF), according to
the criteria developed by the National Multiple Sclerosis So-
ciety [2]. In 2000, another committee of the Society updated
the MS diagnostic criteria. Modern diagnosis of MS requires
additional evidence of lesions in the CNS, disseminated in
t i m ea n ds p a c e ,p r o v i d e dp r i m a r i l yb yM R I .
MS is the most common demyelinating disease, aﬀecting
approximately 350,000 persons in the USA alone. The aver-
ageageattheonsetofMSis32years,andpatientsusuallylive
35 years after the diagnosis [3]. The total cost of MS is esti-
mated at $47,215 per patient and year according to a study
from 2005 (http://ideas.repec.org/p/hhs/hastef/0594.html).
Because disease-modifying drugs account for about 34% of
the total cost, developing sensitive and speciﬁc methods for
monitoring the eﬀectiveness of such treatments would be
highly desirable. This, however, has proven to be diﬃcult.
The reason is the need to extrapolate the results of relatively
short-term studies to the long-term course of MS which is
naturally quite variable with acute attacks followed by rela-
tive stability and/or steady progression [3]. Instead of eval-
uating changes in clinical symptoms, more recent clinical
trials have been aimed at obtaining physical evidence gener-
atedbyMRIforpositivechangesasaresultofthetreatments.
Myelin basic protein (MBP), the proposed target of the
smallmoleculeagentevaluatedforPETimaginginthisstudy,
is the second most abundant protein in the central nervous
system (CNS) myelin after proteolipid protein (PLP). It ac-
countsforapproximately25–30%ofthetotalproteincontent
and 10% of the dry weight of myelin [4]. It is an extrinsic
membrane protein attached to the cytoplasmic side of the
oligodendrocyte membrane. Given their role of myelin-pro-
ducing cells, oligodendrocytes are mostly found in the white
matter, but they also occur in the gray matter, providing
the myelin sheets for axons traversing the gray matter. As
a consequence, MBP can also be found in the gray matter,
although its concentrations in the white matter is 7-8 times
higher [5].2 International Journal of Biomedical Imaging
MS is considered to be an inﬂammatory disease in which
inﬂammation of the blood vessels in the CNS leads to the
destruction of myelin sheets covering the axons of the neu-
rons. The hallmark of MS is the presence of lesions in which
myelin sheaths are damaged to varying degrees. In the same
areas, axons are still present and appear undamaged, embed-
dedinadenseastroglialtissuethatalsocontainslymphocytes
and macrophages. MS lesions are very heterogeneous with
regards to size, composition, location, and possibly even
mechanism of formation. They can be found anywhere in
the CNS but have been most frequently detected in the optic
nerve, in the deep cerebral white matter (especially around
the ventricles), in the cerebellar peduncles, and certain parts
of the brainstem and spinal cord. Old chronic plaques are
gray, hard and sharply demarcated. Fresh lesions, still in
process of myelin destruction, are yellow to brown and of
soft consistency. It is important to note that the lesions do
not completely lack myelin. Myelin loss in these lesions can
range from 10–90%. In very severe cases, there could be
more severe tissue destruction leading to cystic loss of tissue,
mainlyinthecenterofthelesions[3].Fromthepointofview
of the present study, varying myelin content has to be taken
into account when estimating the target concentration in the
lesions.
Even though the plaques have a relatively high con-
centration of sclerotic tissue, they maintain a signiﬁcant
vascular component. Furthermore, increased number and
size of blood vessels were reported in acute lesions. It has
been hypothesized that angiogenesis plays a signiﬁcant role
inpromotingthediseaseprogressionbydeliveringtheagents
maintaining the inﬂammation around blood vessels and
venules [7]. This also means that maintained blood ﬂow will
allow delivery of the imaging agent to the lesions.
In an eﬀort to analyze the size distribution of MS lesions,
Wang and coworkers surveyed the T2 weighted brain MRI
images of 28 patients, 15 with secondary progressive form
(SPMS)and13 withrelapsing remitting formofMS(RRMS)
[6]. Myelin lesions were identiﬁed by experienced observers
using a contouring technique. SPMS patients were found to
have more but smaller lesions compared to RRMS patients.
Overall, 60% of the examined 2766 lesions had diameters
between 3.5 and 9mm, 20% were larger than 9mm and 20%
smaller than 3.5mm (Figure 1). Based on these ﬁndings,
lesion sizes were modeled to be 4–10mm in diameter in this
study.
Currently, MRI is the standard method for imaging MS
lesions. Conventional MRI metrics are routinely used to im-
prove the diagnosis of MS and to monitor the eﬀects of
therapy. T2-weighted MRI imaging is very eﬀective in iden-
tifying MS lesions. However, the areas of increased signal
seen on T2-weighted MRI images reﬂect increased water
content, which is not speciﬁc for MS and cannot provide in-
formation about the degree of myelin destruction in the
lesions.Thisisbecauseotherpathologicalprocessesresulting
in inﬂammation or tissue loss in the brain can result in in-
creased signal [8, 9]. Another technique, T1-weighted imag-
ing following the administration of gadolinium-DTPA, has
been reported to increase the lesion detection rate, but its
use depends on the presence of a leaky blood-brain barrier
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Figure 1: The distribution of lesions according to their sizes in 28
MS patients. The plot has been reproduced based on the ﬁndings
reported by Wang and colleagues and contains data on both SPMS
and RRMS forms of MS [6].
[10–12]. Gadolinium-enhanced MRI studies of patients with
early RRMS were able to detect disruption of the blood-
brain barrier indicating that this method provides a sensitive
measure of at least one aspect of the disease [13, 14]. How-
ever, only weak correlation was found between MRI met-
rics (new/enlarging T2 lesions and gadolinium enhancing
lesions, T2 lesion load, T1 hypointense lesions) and clinical
subtypes and symptoms [15]. It is highly desirable to have an
additional method, such as PET imaging, with high speci-
ﬁcity for MS lesions. Combined with the sensitivity of MRI,
it has the potential to become a practical therapeutic tool.
(E,E)-1,4-bis(p-aminostyryl)-2-methoxy-benzene
( B M B )i sas m a l lm o l e c u l et h a tw a sr e p o r t e dt ob i n d
speciﬁcallyand with high aﬃnity to MBP (Figure 2)[ 16, 17].
Stankoﬀ and coworkers showed that in vitro labeling of
postmortem brain sections allows the identiﬁcation of MS
lesions [16]. They also demonstrated that BMB penetrates
the blood-brain barrier by imaging CNS myelin of baboons
by PET using 11C-labeled BMB as a marker. The study
showed a higher retention rate of BMB in the subcortical
matter than in the adjacent cortex. However, the diﬀerence
was only about 10–20%. The authors speculate that this
might be due to the presence of some myelinated ﬁbers and
the blood-ﬂow-dependent delivery of BMB to the highly vas-
cularized areas of the gray structures [16]. Due to its speci-
ﬁcity for myelin and its ability to cross the blood-brain bar-
rier, BMB or a related molecule with similar properties (la-
beled with an appropriate tracer) might be usable as an
agent for imaging MS lesions with PET. This approach
would complement MRI imaging by providing the desiredInternational Journal of Biomedical Imaging 3
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Figure 2: Imaging agent candidate BMB.
speciﬁcity to diﬀerentiate between lesions of various path-
ological origin detectable by MRI and to monitor treatment
aimed at promoting remyelination.
The purpose of this work was to assess whether BMB or
a similar agent binding speciﬁcally to a component of the
myelinwouldallowthedetectionofMSlesionswithPET.We
used a detailed mechanistic physiology-based pharmacoki-
netic (PBPK) modeling tool to simulate the biodistribution
of the agent in every tissue as a function of time in a human
model with 4–10mm demyelinated lesions in the white mat-
ter of the brain. The agent pharmacokinetics is crucial for
imaging since the overall balance of competing eﬀects such
as speciﬁc binding to the target, nonspeciﬁc binding to sur-
rounding tissues, delivery, and clearance—all within a nar-
rowtimeframe—willdetermineimagequality.Thepredicted
time-dependent agent concentration data and a detailed
anatomical phantom were used as the input to a PET image
simulator to generate images of the model brain with the
MS-type lesions. The images were analyzed to establish
imageability criteria that were then used to deﬁne agent and
physiology property ranges required for successful imaging
(Figure 3).
2. Methods
2.1. PBPK Software. The distribution of BMB in the human
body was simulated with the PBPK modeling software
BioDMET [18], developed at GE Global Research to aid the
development of imaging agents. Ordinary diﬀerential equa-
tions represent the circulation of body ﬂuids through organs
and tissues (macroscopic scale) and the biological transport
mechanisms and biotransformations within cells and their
organelles (molecular scale). Each major organ in the body is
modeled as composed of one or more tissues. The tissues of
the model are made up of cells and ﬂuid spaces. The model
accounts for the circulation of arterial and venous blood
as well as lymph. The use of a PBPK computational model
enables the inclusion of kinetic eﬀects that are critical in
properassessmentofmolecularimagingfeasibility.Examples
of such kinetic eﬀects include agent delivery to the target
location, the competition between target and background
binding rates, partitioning of the agent in the various organs,
and compartments within organs, as well as biliary and renal
clearance rates.
The BioDMET software’s ability to predict drug concen-
trations has been tested using published data on 26 pharma-
ceuticals in 45 individual human and animal models. Good
correlation was obtained between experimentally measured
Table 1: Target/agent properties modeled.
Variable Range of values
Agent molecular weight 342Da
Agent LogP 2–5
Agent administered amount 10−9 moles
Target Myelin Basic Protein (MBP)
Target location CNS myelin in white matter,
gray matter and MS lesions
Target concentration
White matter 1.015 × 10−3 M
Gray matter 1.345 × 10−4 M
MS lesions 1.015 × 10−5–3.61 × 10−4 M
Target molecular weight [25] 18.5kDa
Agent-target binding aﬃnity (Kd)1 0 −6–10−9 M
Agent-target association rate (kon)1 0 5–106 M−1s−1
and calculated log concentrations of drugs/agents in plasma
(R2 = 0.93) and in various other tissues (R2 = 0.89). The
standard deviation in the Log10(measured/calculated) ratios
was 0.39 with a mean value of 0.08 for the plasma, and
0.45 with a mean value of 0.13 for the tissues (Graf et al.,
manuscript in preparation). This level of predictive accuracy
is similar to that found with other PBPK models [19].
2.2. PBPK Model Input Parameters. The whole body physiol-
ogy model of the human organism provided with BioDMET
was customized to include the relevant anatomical details for
MS. The brain was modeled as having three compartments:
white matter, gray matter, and lesions. The water, protein,
and lipid composition of these compartments was set to cor-
respond to the values found in the literature [20–22]. Con-
centration values of MBP in the three compartments used in
this study are averages of the MBP concentrations measured
in various brain regions by radioimmunoassay [23, 24]. The
molecular weight of various MBP isoforms varies between
17.2–21kDa. The molecular weight of the major human
isoform, 18.5kDa, was used in this study [25]. These and
other input parameter values are listed in Tables 1 and 2.
2.3. Phantom with MS Lesions. Artiﬁcial lesions of represen-
tative sizes for MS lesions (spheres of diameters of 4, 6, 8,
and 10mm) were inserted into the white matter of the Zubal
head phantom [26]( Table 3). To assess the imageability of
lesions as a function of location, every lesion of a certain size
was inserted both into a region completely surrounded by
whitematterandintoanotherregionsituatedattheborderof
white and gray matter in the same slice (Figure 4). To locate
appropriate regions and identify their coordinates, the head
phantom was visualized with the program MRIcro [27].
2.4. Image Simulator. Using the time-activity curves calcu-
lated with BioDMET and the parameters of the head phan-
tom, PET images were simulated for realistic ranges of con-
ditions(Table 4)withaprogramdevelopedatGEGRCtoaid
in the design and analysis of system geometries and image4 International Journal of Biomedical Imaging
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Figure 3: Schematic workﬂow of an imaging feasibility study.
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Figure 4: Blue arrows point at lesions inserted into the Zubal head phantom at diﬀerent transverse locations: (a) slice 45, (b) slice 52, (c)
slice 58, and (d) slice 63. According to the coloring scheme of MRIcro, white matter is shown in orange, gray matter in white, and lesions in
black.
generation chains. The PET image simulator used for the
present work is an analytical simulation framework designed
for system-level and image reconstruction algorithm com-
parisons [28]. It is based on accurate physical and statistical
models of imaging systems and can generate system models
that contain the detection probabilities for photons originat-
ing at diﬀerent locations within the subject. These probabil-
ities are precomputed and stored for use in data generation.
Physical events that corrupt the data, such as scattering and
random (PET only) events, as well as attenuation within
the patient and variable detector eﬃciencies are also taken
into account for more accurate simulations of real imagingInternational Journal of Biomedical Imaging 5
Table 2: Tissue composition and target concentration in the
modeled brain compartments.
White matter Gray matter MS lesion
Mass fraction of brain
(%) 42 56 2
Water fraction
[21]( % ) 72 82 76
Total protein
(% dry weight) [21] 39 55.3 31.7
Total protein
(% wet weight) 10.92 9.954 7.608
Total protein
(g/g wet weight) 109.2 × 10−3 99.54 × 10−3 76.08 × 10−3
MBP
(mg/g protein) 172 [24]2 5 [ 23] 87.8 [24]
MBP
(mg/g wet weight) 18.7824 2.4885 6.679824
MBP (Molar
concentration) 1.015 × 10−3 1.345 × 10−4 3.61 × 10−4
systems. Statistical noise that is present in the data, and is
often a limiting factor for the resolution/noise tradeoﬀsi n
the imaging systems, is modeled as additive, independent
Poisson noise. The ﬁnal system model is then calibrated to
directly relate activity concentrations within the subject to
counts measured at each detector element. The following
input acquisition parameters were used for the PET simu-
lator:
(i) interval between time points of the time-activity
measurement: 2min,
(ii) scan duration: 20min,
(iii) injected dose: 10mCi,
(iv) time between injection of imaging agent and scan
start: 2h,
(v) half life of radioisotope: 6588s,
(vi) % Positron yield of radio-isotope: 0.97.
2.5. Image Analysis to Determine Signal-to-Noise Ratios.
Slices of simulated PET images dissecting the regions at
the center of the lesions were analyzed with the program
OriginPro 8. To assess imageability, the signal-to-noise ratio
was calculated for each lesion the following way. Images with
activities modeled only in the lesions were used to deﬁne
the location and area of the lesions on the simulated images.
Pixels were counted as part of the lesion if the signal intensity
was above the cutoﬀ deﬁned by:
Cutoﬀ =
MaxSignal − Baseline
4
, (1)
wherethebaselineisthemeansignalintensitycalculatedover
the entire image. This is equivalent to deﬁning the area of the
peak (signal) at 25% of its height (Figure 5(a)).
Raising the cutoﬀ well above the baseline was done to
provide a cleaner signal by excluding pixels on the periphery
of the lesion with smaller ﬂuctuations and to increase the
likelihood thattheregion identiﬁed withasignalbelonged to
the lesion. Factors contributing to the noise can be technical
and physiological in nature: the inherent limitations of the
imaging technology (∼15% scatter fraction reported for the
2D data acquisition mode) [29]a sw e l la sv a r i a t i o n si nt h e
brain structure; in this particular case the uneven distri-
bution of myelin within the diﬀerent compartments of the
brain, irregular delimitation of white matter, gray matter and
lesions, and variation of myelin content inside the lesions.
Signal-to-noise ratio in imaging is generally deﬁned as
the ratio of the mean signal intensity and the standard de-
viation of the background intensity [30]( Figure 5):
SNR =
μSignal
σBGR
. (2)
In the case of MS lesion imaging, the situation is diﬀerent
since the task is to detect a decrease in signal intensity in
lesions inserted into a high activity background (“negative”
signal, Figure 5(c)). As a consequence, we used the following
modiﬁed formula for the signal-to-noise ratio calculation:
SNR =
μBGR −μLES
σBGR
,( 3 )
where μBGR is the mean intensity of the background mea-
sured on the image without lesion, μLES is the mean intensity
insidethelesion,andσBGR representstheﬂuctuationsaround
the background (standard deviation). To evaluate the mean
of the background signal, PET image simulations were run
in pairs on the lesion-free and lesion-containing phantoms
for every condition examined. After determining the lesion
location and area on the lesion-only image (Figure 6(a)), as
described above, the mean intensities were calculated for the
corresponding pixels on the lesion-free (μBGR) and lesion-
containing images (μLES) as shown in Figures 6(b) and 6(c).
The standard deviation from the mean of the intensities
on the lesion-free image (μBGR) served as the measure of
background noise (σBGR).
2.6.BiodistributionScoring. Indiagnosticimaging,avalueof
3 to 5 for SNR is considered desirable in order to clearly
delineate a region of interest [30]. For the purpose of this
study,weconsideredaregionwithaSNR>2tobeimageable.
An SNR <1isconsideredtobenotimageablesincethesignal
is of comparable intensity to the noise. Lesions with SNR
values between 1 and 2 might be imageable depending on a
number of factors such as available reference (background),
experience of observer, or software used for image analysis.
These SNR cutoﬀ values were set while assuming that cor-
egistered MRI images were to be used to locate the lesions
and deﬁne their areas. Once the location and accurate size
of the region of interest (ROI) was determined, an algorithm
would compare the coregistered PET signal originating from
the ROI with the background signal of the normal-looking
surrounding white matter. Instead of just relying on the
ability of the human eye to detect the lesion, this would al-
low the use of simple statistical analysis to decide whether
the region of interest has a signiﬁcantly lower average signal6 International Journal of Biomedical Imaging
Table 3: Sagittal (x), coronal (y), and transverse (z) coordinates of lesions inserted into the white matter of the Zubal head phantom.
Diameter (mm)
Location
Completely within the white matter At the border or white and gray matter
xyz x y z
4 103 123 52 142 144 52
6 106 84 63 144 86 63
8 110 105 45 139 140 45
10 151 127 58 109 141 58
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Figure 5: Deﬁning the area of a lesion (a). Positive (b) and negative (c) signals.
relative to the background for a positive MS lesion identiﬁ-
cation.
3. Results
3.1. Acquisition Time. It is known that longer acquisition
times result in sharper images [30], although they lead to
increase in patient discomfort. To explore the eﬀect of ac-
quisition time on SNR, images of brain slices with 8mm
lesions simulated using 10 and 20min acquisition times were
compared. The result showed a 40% higher SNR for 20min
acquisition time (SNR = 1.01) relative to a 10min one
(SNR = 0.61, data not shown). Based on this ﬁnding, 20min
acquisition time was used for all subsequent simulations.
3.2. BioDMET Parameter Sensitivity Analysis. The PET im-
age quality is primarily determined by the pharmacokinetics
of the agent, which translates into activity ratios detected in
white matter and gray matter relative to the lesions. The ac-
tivity ratio, on its turn, is a direct reﬂection of the agent con-
centration ratios in these compartments. To better under-
stand the agent and target properties that can aﬀect image-
ability, a parameter sensitivity analysis was performed by
varying the following input parameters: target concentration
in the lesions, plasma protein binding, liver clearance, logD,
speciﬁc binding aﬃnity (Kd), and binding on rate (kon)o f
the agent. Output parameters monitored were agent con-
centrations in the white and gray matter relative to the
concentration in the lesions at 2 hours following administra-
tion, which corresponds to the image acquisition start time.International Journal of Biomedical Imaging 7
(a) (b) (c)
Figure 6: Identifying lesion location on simulated PET images with activity modeled only in lesions (a). The background intensity was
calculated in the same area on the lesion-free image (b). The signal intensity was derived from the same area of the image containing the
lesions (c). The area of interest is circled in red on (a, b, c). The lesion size in this series of images is 8mm.
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Figure 7: The eﬀect of model input parameters on the activity diﬀerences in the white matter and the lesion. (a) Sensitivity coeﬃcients
relative to agent and target properties. (b) The inﬂuence of agent logP on the white matter-lesion activity ratio.
The sensitivity coeﬃcient of the output parameter i relative
to the input parameter j was calculated according to the
formula
SCi,j =
ΔYi
ΔXj
(4)
where ΔYi is the percent change in the output parameter i
due to a ΔXj relative change in input parameter j. Table 4
lists the input parameter values used in the calculations.
The agent concentration ratios in white matter versus le-
sion and gray matter versus lesion were found to be the most
sensitive to the target concentration in the lesion and the
agent binding aﬃnity for the target as indicated by the values
of the sensitivity coeﬃcients (Figure 7(a)).
ThelogP rangeof4-5examinedinthesensitivityanalysis
corresponds to a highly lipophilic compound such as BMB,
which is expected to partition signiﬁcantly into the myelin of
the brain. Decreasing the logP of the compound below a val-
ue of 4 would increase solubility but, at the same time, it is
expected to negatively aﬀect myelin partitioning. To verify
this, the activity ratio in the white matter relative to the le-
sions was calculated for several values in the wider logP
range of 2–5 as a function of time after administration. Not
surprisingly, the eﬀect of logP on the biodistribution ratio
was found to be nonlinear and increasingly detrimental to8 International Journal of Biomedical Imaging
Table 4: Input parameters used for the sensitivity coeﬃcient calculations.
Run no. Description Plasma protein
binding
Liver microsomal
clearance rate Log P
Target conc.
Kd kon
Sensitivity coeﬃcient
WM/Lesion GM/Lesion
(%) (mL/min/mg
protein) (M) (M) (M−1s−1)
(1) Baseline 10 8 × 10−3 43 . 6 1 × 10−4 1 × 10−6 5.5 × 105 ——
(2) % PPB 20 8 × 10−3 43 . 6 1 × 10−4 1 × 10−6 5.5 × 105 2.693 × 10−2 −2.661 × 10−2
(3) LM CL 10 8.8 × 10−3 43 . 6 1 × 10−4 1 × 10−6 5.5 × 105 2.534 × 10−2 −4.785 × 10−2
(4) LogD 10 8 × 10−3 53 . 6 1 × 10−4 1 × 10−6 5.5 × 105 2.967 × 10−2 −3.242 × 10−2
(5) Target conc. 10 8 × 10−3 45 . 4 2 × 10−4 1 × 10−6 5.5 × 105 −3.984 × 10−1 −3.995 × 10−1
(6) Kd 10 8 × 10−3 43 . 6 1 × 10−4 2 × 10−6 5.5 × 105 3.115 × 10−1 −1.668 × 10−1
(7) kon 10 8 × 10−3 43 . 6 1 × 10−4 1 × 10−6 1.0 × 106 −1.526 × 10−5 −6.893 × 10−5
the activity diﬀerences between these two regions. A drop of
2l o gP units from 4 to 2 resulted in a roughly 40% decrease
in the activity ratio between the white matter and the lesion.
However, a one-unit decrease in the logP f r o m4t o3c a u s e d
only a 10% decrease in the activity ratio (Figure 7(b)). For a
myelin-speciﬁc agent, a logP a b o v e3s e e m st ob en e c e s s a r y
to produce signiﬁcant diﬀerences between the white matter
and MS lesions.
Next, we explored what regions of the parameter land-
scape could maximize the concentration ratios at 2 hours
after agent administration, and, as a consequence, would
maximize imageability. For this, 500 PBPK simulation runs
were performed during which both the binding aﬃnity
and the target concentration in the lesions were sampled
simultaneously using a Monte Carlo algorithm in the 10−6–
10−9 Ma n d1 0 −4–9 × 10−4 M range, respectively. The agent
concentration ratio in the white matter relative to the lesions
was monitored as the independent variable and the mea-
sure of imaging feasibility. As expected, more pronounced
demyelination leading to lower target concentration in the
lesionsresultedinhigheragentconcentrationratios.Binding
aﬃnity showed a somewhat surprising trend: weaker, not
stronger binding (higher Kd)r e s u l t e di nh i g h e rc o n c e n t r a -
tion ratios (Figure 8), suggesting better imageability.
3.3. Binding Aﬃnity and Target Concentration Eﬀects. Agent
concentration in white matter versus lesions is an important
determinantofimageability,butitisnottheonlyone.Lesion
location, size, and inherent limitations of the methodology
have to be taken into account as well. Therefore, several spe-
ciﬁc parameter combinations were used to calculate the cor-
responding agent biodistribution and generate simulated
PET images for these conditions. The eﬀect of lesion size and
location was also evaluated. Lesions next to gray matter
are expected to be more diﬃcult to detect since the myelin
content of the lesions is more similar to the myelin content
of the gray matter than that of the white matter. Image anal-
ysis followed to determine the signal-to-noise ratios in the
regions of interest containing the lesions inserted into the
head phantom. Four sets of biodistribution (time-activity)
curvesareshowninFigure 9asanexample.Thetime-activity
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Figure 8: Heatmap of white matter/lesion agent concentration
ratios as a function of target concentration in the lesion and agent
binding aﬃnity to the target. Imageability increases from red to
green, with red regions corresponding to conditions that would
make imaging impossible and green regions to conditions that
would enable imaging of MS lesions imbedded in the white matter.
curves reﬂect the total activity resulting from both bound
and free agent. Besides speciﬁc binding to the target, non-
speciﬁc binding to proteins present in every tissue with a Kd
= 10−3 M is also accounted for.
Signiﬁcant activity diﬀerences between the white matter
and lesions could be observed only if the binding aﬃnity was
drastically decreased by three orders of magnitude (Figures
9(a) and 9(b)). At nanomolar binding aﬃnities, the activity
levels were found to be relatively insensitive to even a 35-
fold additional decrease in MBP concentration in the lesions
(Figure 9(c)). In contrast, an agent with micromolar binding
aﬃnity was predicted to be quite sensitive to a much small-
er 3.5-fold additional decrease in MBP concentration within
the lesions (Figure 9(d)). The activity levels remained un-
changed upon 10-fold increases in kon rates.
Simulated PET images of the head phantom were gen-
erated with and without lesions, and SNR values were cal-
culated for every lesion location in every parameter com-
bination. The results shown in Figure 10(a) refer to lesions
located entirely within the white matter, and in Figure 10(b)International Journal of Biomedical Imaging 9
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Figure 9: Time-activity curves for diﬀerent Kd values and MBP concentrations in the lesions: (a) [MBP] = 3.61 × 10−4 M, Kd = 10−9 M; (b)
[MBP] = 3.61 × 10−4 M, Kd = 10−6 M; (c) [MBP] = 1.015 × 10−5 M, Kd = 10−9 M; (d) [MBP] = 1.015 × 10−4 M, Kd = 10−6 M.
to the lesions near the border of white and gray matter.
Imaging was considered to be not feasible for SNR < 1( r e d ) ,
m a y b ef e a s i b l ef o r1 ≤ SNR < 2 (yellow), and feasible for SNR
≥ 2( g r e e n ) .
Based on the sets of conditions examined, imaging of MS
lesions is predicted to be feasible under the following con-
ditions:
(i) binding aﬃnity of the imaging agent to the target in
the micromolar range (0.5–1μM),
(ii) myelin content of the lesions reduced at least 10-fold
relative to the normal levels,
(iii) lesions larger than 6mm in diameter,
(iv) lesions completely (or mostly) surrounded by white
matter.
If the lower threshold of the SNR for “maybe” imageable is
set to 1.3 instead of 1 (equivalent to a diﬀerence of 1.3σBGR
between the mean of the signal and that of the noise), only
lesions larger than 8mm in diameter will be considered vis-
ible on PET images.
3.4. Accurate Lesion Localization. To evaluate the eﬀect of ac-
curate determination of lesion size and location, the area of
the lesions was increased 50% by including adjacent pixels
in the determination of signal intensities both on the images
with and without lesions. The calculations were done for
the lesions completely embedded in the white matter with
a 100-fold reduced myelin concentration and imaging agent
binding aﬃnity of 1000nM. Signal-to-noise ratios decreased
signiﬁcantly for every lesion with 35–55% (Figure 11).10 International Journal of Biomedical Imaging
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4. Discussion
In clinical imaging applications, a key parameter is image-
ability, which is a complex function of biodistribution and
clearance, and ultimately depends on the signal-to-noise
(or signal-to-background) ratio achieved at the target at a
particular point in time. In order to establish imageability
criteria for reversible binders such as BMB, it is important
to have a time frame suﬃciently long for image acquisition
during which a sustained concentration ratio between the
target tissue and the background can be achieved. If this
conditioncanbesatisﬁed,asinoursimulations,imageability
criteria can be formulated in spite of the changing agent
concentrations over time. Ultimately, as more experimental
data is collected, the simulations can be further reﬁned and
the time-dependence of the signal-to-noise ratio can be de-
termined more accurately.
Besidesdeﬁningspeciﬁcconditionsunderwhichimaging
is predicted to be feasible, the present feasibility study pro-
vided a few additional insights detailed below.
4.1. Accurate Determination of Location and Size of the Lesions
is Critical. MS lesions are usually sharply demarcated from
the surrounding tissue in the MS brain when examined at
autopsy. The limited resolution of PET imaging and the non-
uniform distribution of the target in the brain, however, will
result in decreased intensity spots with blurred borders on
a background with uneven intensity. Since MS lesions are
relatively small (median diameter 5-6mm) and the change
in the average signal intensity within the lesions is only about
10–30% when compared to the surrounding background, it
will be a challenge to locate them on a PET image and de-
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Figure 11: The eﬀect of accurate lesions delineation on SNR.
Relaxing the criteria of what pixels are included in the lesions to
allow a 50% increase in lesion area resulted in 35–55% decrease in
SNR.
termine their area accurately. Overcoming this challenge is
important for a good signal-to-noise ratio, as shown earlier.
Combining MRI and PET imaging might be the solution to
this problem. The higher resolution of MRI would allow
accurate localization of the lesions, whereas PET would
enable speciﬁc measurement of their myelin content. Deter-
miningthebackgroundintensitycouldalsobeaidedbyMRI,
which would be used to delineate the region correspondingInternational Journal of Biomedical Imaging 11
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Figure 12:Protein-ligandbindingkinetics:thefractionofboundligandconcentrationdependsonthetotaltargetandligandconcentrations
and the binding aﬃnity.
to white matter. The average intensity of this region could
serve as the reference to which the intensity of the lesions is
compared.
4.2. Stronger Binding Agent Might Not Always Be the
Most Favorable. The fact that agents with lower Kd values
(stronger binders) are worse than weaker binders when it
comes to diﬀerentiating between regions of diﬀerent target
concentrationsmightnotnecessarilybeintuitive.Thissome-
what unexpected behavior is due to the high target/agent
concentration ratios both in the white matter and in the
lesions and to the nonlinear, saturable kinetics of protein-
ligand binding. The percent bound ligand as a function of
thetargetandligandconcentrationandthebindingaﬃnityis
showninFigure 12.Havingatargetconcentrationofapprox-
imately 10−4 M and a nanomolar binder ([Target]/Kd =
105) with [Ligand]/Kd ratio of 1 (green curve in Figure 12)
will result in 100% bound ligands in the lesions. The 10-
fold excess of target concentration in the white matter will
decrease the [Target]/Kd ratio to 104, but this will still result
in practically 100% agent binding. Since the target/agent
concentrationratioisextremelyhigh(∼105 to 106),a10-fold
decrease in target concentration in lesions might decrease
the bound ligand concentration with about 0.001%. The
consequence is that the entire amount of the agent reaching
the normal white matter, the gray matter or the lesions
will bind, and no diﬀerence between the activity levels in
these regions will be detected. Diﬀerential binding, and,
consequently, diﬀerent activities could be achieved if the
target concentrations in the lesions were several orders of
magnitude lower than in the normal appearing white matter
orbyusingaconsiderablyweakerbinderasanimagingagent.
Weaker binders, however, might result in loss of speciﬁcity.
The optimal scenario would be to have an MS lesion-speciﬁc
marker that is not present in the white matter. The binding
aﬃnities of ligands against such a marker are not subjects to
upper constraints. These are the straightforward cases when
the stronger the binding the better the SNR.
4.3. Longer Acquisition Times Might Be Necessary for Better
Diﬀerentiation of Lesions. A compromise has to be reached
between the patient discomfort caused by having to lie still
inside the scanner for an extended period of time and the
need for longer acquisition times to obtain sharper images
of the lesions. Even a 20-minute acquisition time resulted
in relatively weak SNR; decreasing this time to 10 minutes
would weaken the signals about 40% to the point where
imageability would not be feasible under any conditions.
Increasing the acquisition time even further (to 30 minutes
or higher) would most likely be too uncomfortable for the
patients. Based on this study, a 20-minute acquisition time
seems to be most reasonable.
As a summary, our study indicates that PET imaging of
MS lesions is far from being a trivial task. PET images would
be useful by providing speciﬁcity for MS lesions, but they
should be coregistered with MRI images to spot the lesions
and delineate them accurately. Imaging agents that are rel-
atively weak (micromolar) binders but speciﬁc for a compo-
nent of myelin could be used to obtain discernable images of
lesions with diameters of about 6mm or larger embedded
into the white matter if the myelin-speciﬁc target content
of these lesions is at least 10-fold reduced relative to the
surrounding tissue.
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